Related Experiment Video
Updated: Feb 14, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial
Ioanna Kosmidou1, Shmuel Chen2, A Pieter Kappetein3
1Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Arrhythmia Center, Department of Cardiology, St. Francis Hospital, Roslyn, New York.
Insights
New-onset atrial fibrillation (NOAF) is common after coronary artery bypass grafting (CABG) but rare after percutaneous coronary intervention (PCI) for left main coronary artery disease. NOAF after CABG significantly increases the risk of stroke and death.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Limited data exists on new-onset atrial fibrillation (NOAF) incidence and outcomes post-revascularization for left main coronary artery disease (LMCAD).
- Understanding NOAF's impact after PCI versus CABG is crucial for patient management.
Purpose of the Study:
- To assess the incidence of NOAF following PCI and CABG in LMCAD patients.
- To evaluate the 3-year cardiovascular outcomes associated with NOAF post-revascularization.
Main Methods:
- Analysis of the EXCEL trial data, randomizing 1,905 LMCAD patients to PCI or CABG.
- Outcomes were compared between patients who developed NOAF during hospitalization and those who did not.
Main Results:
- NOAF occurred in 18.0% of CABG patients versus 0.1% of PCI patients (p < 0.0001).
- NOAF was linked to longer hospital stays, increased anticoagulant use, and higher bleeding rates.
- NOAF post-CABG independently predicted 3-year stroke (aHR 4.19), death (aHR 3.02), and composite endpoints (aHR 2.13).
Conclusions:
- NOAF is frequent after CABG but rare after PCI for LMCAD.
- NOAF development post-CABG is a significant predictor of adverse long-term cardiovascular outcomes.
- Further research into prophylactic strategies for NOAF in CABG patients is warranted.
Background:
There is limited information on the incidence and prognostic impact of new-onset atrial fibrillation (NOAF) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD).
Objectives:
This study sought to determine the incidence of NOAF following PCI and CABG for LMCAD and its effect on 3-year cardiovascular outcomes.
Methods:
In the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with LMCAD and low or intermediate SYNTAX scores were randomized to PCI with everolimus-eluting stents versus CABG. Outcomes were analyzed according to the development of NOAF during the initial hospitalization following revascularization.
Results:
Among 1,812 patients without atrial fibrillation on presentation, NOAF developed at a mean of 2.7 ± 2.5 days after revascularization in 162 patients (8.9%), including 161 of 893 (18.0%) CABG-treated patients and 1 of 919 (0.1%) PCI-treated patients (p < 0.0001). Older age, greater body mass index, and reduced left ventricular ejection fraction were independent predictors of NOAF in patients undergoing CABG. Patients with versus without NOAF had a significantly longer duration of hospitalization, were more likely to be discharged on anticoagulant therapy, and had an increased 30-day rate of Thrombolysis In Myocardial Infarction major or minor bleeding (14.2% vs. 5.5%; p < 0.0001). By multivariable analysis, NOAF after CABG was an independent predictor of 3-year stroke (6.6% vs. 2.4%; adjusted hazard ratio [HR]: 4.19; 95% confidence interval [CI]: 1.74 to 10.11; p = 0.001), death (11.4% vs. 4.3%; adjusted HR: 3.02; 95% CI: 1.60 to 5.70; p = 0.0006), and the primary composite endpoint of death, MI, or stroke (22.6% vs. 12.8%; adjusted HR: 2.13; 95% CI: 1.39 to 3.25; p = 0.0004).
Conclusions:
In patients with LMCAD undergoing revascularization in the EXCEL trial, NOAF was common after CABG but extremely rare after PCI. The development of NOAF was strongly associated with subsequent death and stroke in CABG-treated patients. Further studies are warranted to determine whether prophylactic strategies to prevent or treat atrial fibrillation may improve prognosis in patients with LMCAD who are undergoing CABG. (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Microsoft Excel: Plotting Mean, SD, and SE
First, calculate the mean, SD, and SE of your data. The mean is obtained using the formula `=AVERAGE(range)`, while SD can be calculated with `=STDEV.P(range)` for a population or `=STDEV.S(range)` for a sample. SE is calculated as `=SD/SQRT(n)`, where `n` is the sample size.
To plot these values, use a bar...
Microsoft Excel: Student's t-Test
To conduct a t-test in Excel, use the T.TEST function or the "Data...
Microsoft Excel: Pearson's Correlation
Microsoft Excel: Regression Analysis
To perform regression...

